Randomized Trial of a Third Dose of mRNA-1273 Vaccine in Transplant Recipients

• Published in: The New England journal of medicine Vol. 385; no. 13; pp. 1244 - 1246
• Main Authors: Hall, Victoria G, Ferreira, Victor H, Ku, Terrance, Ierullo, Matthew, Majchrzak-Kita, Beata, Chaparro, Cecilia, Selzner, Nazia, Schiff, Jeffrey, McDonald, Michael, Tomlinson, George, Kulasingam, Vathany, Kumar, Deepali, Humar, Atul
• Format: Journal Article
• Language: English
• Published: United States Massachusetts Medical Society 23.09.2021
• Subjects: 2019-nCoV Vaccine mRNA-1273; Antibodies; Antibodies, Neutralizing - blood; Antibodies, Viral - blood; Confidence intervals; Coronavirus; Coronaviruses; Correspondence; COVID-19 - prevention & control; COVID-19 vaccines; COVID-19 Vaccines - administration & dosage; COVID-19 Vaccines - immunology; Health care networks; Humans; Immunization, Secondary; Immunogenicity, Vaccine; Infectious Disease; Kidney Transplantation; mRNA; mRNA vaccines; Nephrology; Organ Transplantation; Patients; Placebos; Regulatory approval; SARS-CoV-2 - immunology; Severe acute respiratory syndrome coronavirus 2; Transplant Recipients; Transplants & implants; Vaccination; Vaccines
• ISSN: 0028-4793; 1533-4406; 1533-4406
• DOI: 10.1056/NEJMc2111462

It is known that people receiving immune suppressive therapy, such as recipients of solid-organ transplants, have a suboptimal response to SARS-CoV-2 vaccination. In a randomized, double-blind trial, a third dose of the mRNA-1273 vaccine was compared with placebo. The third dose of vaccine produced a significant boost in neutralizing antibodies.